Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing

Posted:

Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped Sangamo said it is now looking for a new partner for the program.

Read the full article in the latest MedCity News blog post here.

Previous post
Back to list
Next post